The global atherosclerosis market is on track to attain USD 47,637.4 million by 2025, expanding at a compound annual growth rate (CAGR) of 2.7%, reaching USD 62,180.3 million by 2035. The revenue generated by therapeutic apheresis in 2024 was approximately USD 46,430.2 million, highlighting the market’s strong foothold in cardiovascular disease management.

Atherosclerosis continues to pose a significant challenge to global healthcare systems as cardiovascular diseases remain among the leading causes of morbidity and mortality worldwide. The market is witnessing a paradigm shift driven by rising disease prevalence, groundbreaking drug approvals, and the introduction of innovative non-invasive treatment strategies.

With the rising burden of cardiovascular diseases, the global healthcare sector remains committed to developing and adopting more efficient treatment solutions. As research and development initiatives gain momentum, the atherosclerosis market is set for substantial transformation over the next decade.

“Atherosclerosis treatment is evolving rapidly with the integration of precision medicine and novel therapeutic approaches. The introduction of PCSK9 inhibitors and advancements in gene editing signify a major shift toward long-term disease management. As pharmaceutical companies continue to invest in cutting-edge biotechnologies, we anticipate a sustained growth trajectory in the market,”

The atherosclerosis market is highly competitive, driven by the rising prevalence of cardiovascular diseases and the introduction of advanced treatment strategies. Pharmaceutical and medical device companies are increasingly focusing on innovative drugs and surgical procedures to enhance patient outcomes.

Significant emphasis has been placed on research and development (R&D) investments, securing regulatory approvals, and forming strategic collaborations to strengthen market positioning. The competitive landscape is shaped by a mix of well-established pharmaceutical firms and emerging biotechnology companies, each contributing to the market’s dynamic growth.

Drug Type and Interventional Devices

Atherosclerosis, Medial Calcificsclerosis, Arteriolosclerosis and Mönckeberg Arteriosclerosis

Hospital, Cardiac Catheterization Labs, Retail Pharmacies, Online Pharmacies

By Region:

North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube